The utility of the Edmonton Obesity Staging System for the prediction of COVID-19 outcomes: a multi-centre study.
Marcela Rodríguez-FloresEduardo W Goicochea-TurcottLeonardo Mancillas-AdameNayely Garibay-NietoMalaquías López-CervantesMario E Rojas-RussellLilia V Castro-PorrasEduardo Gutiérrez-LeónLuis F Campos-CalderónKaren Pedraza-EscuderoKarina Aguilar-CuartoEréndira Villanueva-OrtegaJoselín Hernández-RuizGuadalupe Guerrero-AvendañoSheyla M Monzalvo-ReyesRafael García-RascónIsrael N Gil-VelázquezDora E Cortés-HernándezMarcela Granados-ShiromaBrenda G Alvarez-RodríguezMartha L Cabello-GarzaZaira L González-ContrerasEsteban Picazo-PalenciaJuana M Cerda-ArteagaHéctor R Pérez-GómezRoberto Calva-RodríguezGerardo Sánchez-RodríguezLeslie D Carpio-VázquezMaría A Dávalos-HerreraKarla M Villatoro-de-PleitezMelissa D Suárez-LópezMaría G Nevárez-CarrilloKarina Pérez-AlcántaraRoopa MehtaEdurne Sandoval DiezEdward W GreggPublished in: International journal of obesity (2005) (2022)
EOSS was associated with adverse COVID-19 outcomes, and it distinguished risks beyond BMI. Patients with overweight and obesity in EOSS stages 0 and 1 had a lower risk than patients with normal weight. BMI does not adequately reflect adipose tissue-associated disease, it is not ideal for guiding chronic-disease management.